OncoResponse Adds $7M As Part of Series A Extension

Houston-based OncoResponse, the biotech developer which is developing antibodies for the cancer immunotherapy market, said earlier this week that it has raised $7M as part of a "supplemental" Series A financing. The company said the funding included $3.5M from GreatPoint Ventures, and another $3.M from Helsinn Investment Fund. The company sid that the Series A funding brings it total raised in the Series A funding to $19.5M, and that it is hoping to eventually boost the Series A to $22.5M. The company said the funding goes towards its antibody discovery efforts.